Welcome to our dedicated page for Pacira BioSciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira BioSciences stock.
Pacira BioSciences reports developments across a commercial portfolio of non-opioid pain management and regenerative health products. Its recurring updates center on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain, ZILRETTA® extended-release intra-articular corticosteroid injection for osteoarthritis, and the iovera° cold-therapy device for targeted nerve pain control.
Company news also covers earnings and product revenue trends, real-world evidence on opioid use and healthcare costs, pipeline development involving ZILRETTA, iovera° and PCRX-201, share repurchases, equity inducement awards, and stockholder governance matters tied to board composition and proxy materials.
Pacira BioSciences (Nasdaq: PCRX) announced a positive opinion from the European Medicines Agency’s CHMP recommending marketing authorization for its pain management drug, EXPAREL, for postsurgical analgesia. This recommendation was supported by four pivotal studies highlighting EXPAREL's effectiveness in reducing pain scores and opioid use in various surgical settings. A final European Commission decision is expected in November 2020. This step aligns with Pacira's vision to lead in non-opioid pain management, with EXPAREL already utilized in over seven million patients in the U.S.
Pacira BioSciences (PCRX) and IPG have announced a partnership aimed at reducing postsurgical opioid prescriptions and lowering surgical costs across IPG's health plan network. The collaboration will see IPG reimbursing for EXPAREL®, a non-opioid pain management solution, to enhance surgical care quality and affordability. Both companies will create educational resources to optimize pain management practices, with Pacira emphasizing the benefits of non-opioid approaches for improved patient outcomes and satisfaction.
PARSIPPANY, N.J., Sept. 11, 2020 - Pacira BioSciences, Inc. (NASDAQ: PCRX) will present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020, at 3:30 PM ET. Interested parties can listen to the live audio through the company’s website. A replay will be available for two weeks post-event. Pacira specializes in non-opioid pain management solutions, with its flagship product, EXPAREL®, launched in April 2012. The firm advocates for reduced opioid reliance in healthcare.
Pacira BioSciences (PCRX) reported preliminary August 2020 net product sales of EXPAREL at $36.1 million, reflecting average daily sales at 111% of 2019 levels. The rise in sales is attributed to the growing adoption of EXPAREL among surgical centers and anesthesiologists, driven by a shift towards outpatient procedures as restrictions on elective surgeries ease amid COVID-19. The company aims to provide transparency by reporting monthly sales until full visibility on pandemic impacts is achieved. Financial data is preliminary and unaudited.
Pacira BioSciences (Nasdaq: PCRX) reported Q2 2020 revenues of $75.5 million, down 26% from $102.6 million in Q2 2019, largely due to the impacts of COVID-19. EXPAREL net sales were $73.0 million, also down by 26%. The company’s GAAP net loss reached $7.3 million ($0.17 per share), contrasting with a net income of $2.7 million in the same period last year. Total operating expenses decreased to $82.7 million. Pacira has seen a recovery in EXPAREL sales since April and aims to expand its non-opioid pain management solutions. The FDA accepted an sNDA for EXPAREL for pediatric use, with an expected decision by March 2021.
Pacira BioSciences, Inc. (NASDAQ: PCRX) will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on August 11, 2020, at 9:10 AM ET. Interested parties can access the live audio via the company’s website. A webcast replay will be available for two weeks post-event. Pacira specializes in non-opioid pain management solutions, including EXPAREL® and the iovera⁰ system.
Pacira BioSciences announced the publication of its Phase 4 study results for EXPAREL in Anesthesia and Analgesia. The study showed a 52% reduction in total opioid consumption at 72 hours post-C-section when combined with bupivacaine, and a statistically significant increase in opioid-spared patients (54% vs 25%). The study spanned 13 sites and involved 136 patients. Safety was comparable between groups, with 64% of the EXPAREL group experiencing treatment-emergent adverse events. This data could enhance postoperative pain management strategies, especially given that C-sections pose significant opioid use concerns.
Pacira BioSciences announced that the FDA has accepted its supplemental new drug application (sNDA) for EXPAREL, aiming to expand its label to include postsurgical analgesia for children aged six and over. Based on positive Phase 3 study results showing favorable pharmacokinetics and safety profiles, the FDA's action date is set for March 22, 2021. If approved, EXPAREL will become the first long-acting local anesthetic sanctioned for pediatric use, addressing the urgent need for non-opioid pain management alternatives in children, who typically rely on opioids for post-surgery pain relief.
Pacira BioSciences, Inc. (NASDAQ: PCRX) will report its second quarter financial results on August 6, 2020, before market opening. Following the announcement, a live conference call will take place at 8:30 a.m. ET. Participants can join via a dedicated dial-in number or through a webcast available on the company’s investor page. A replay of the call will be accessible for one week post-event. Pacira specializes in non-opioid pain management and regenerative health solutions, prominently featuring its long-acting analgesic, EXPAREL®, launched in April 2012.
Pacira BioSciences, Inc. (Nasdaq: PCRX) has resolved all investigations by the U.S. Department of Justice and other agencies regarding its marketing of EXPAREL®. The settlement amounts to approximately $3.5 million, though Pacira denies any wrongdoing. This conclusion follows a five-year investigation into the company's sales practices. Pacira's chief administrative officer expressed satisfaction in closing this chapter while reaffirming their commitment to legal compliance and non-opioid pain management solutions.